189 related articles for article (PubMed ID: 37307230)
1. Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Wu R; Dennison JB; Peterson CB; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Jha S; Rivero JD; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM; Katayama H
J Clin Endocrinol Metab; 2023 Nov; 108(12):3260-3271. PubMed ID: 37307230
[TBL] [Abstract][Full Text] [Related]
2. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Murage E; Wu R; Dennison JB; Krishna H; Peterson CB; Lozano G; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Del Rivero J; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4969-e4980. PubMed ID: 34318891
[TBL] [Abstract][Full Text] [Related]
3. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.
Hackeng WM; van Beek DJ; Kok ASM; van Emst M; Morsink FHM; van Treijen MJC; Borel Rinkes IHM; Dreijerink KMA; Offerhaus GJA; Valk GD; Vriens MR; Brosens LAA
Am J Surg Pathol; 2022 Feb; 46(2):159-168. PubMed ID: 34560682
[TBL] [Abstract][Full Text] [Related]
6. Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors.
Diedisheim M; Dermine S; Jouinot A; Septier A; Gaujoux S; Dousset B; Cadiot G; Larger E; Bertherat J; Scharfmann R; Terris B; Coriat R; Assié G
Endocr Relat Cancer; 2021 Jun; 28(8):563-571. PubMed ID: 34061769
[TBL] [Abstract][Full Text] [Related]
7. Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort.
van Beek DJ; Nell S; Vorselaars WMCM; Bonsing BA; van Eijck CHJ; van Goor H; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; ; Borel Rinkes IHM; Vriens MR
Ann Surg Oncol; 2021 Aug; 28(8):4387-4399. PubMed ID: 33521900
[TBL] [Abstract][Full Text] [Related]
8. The Search for a Reliable Biomarker in MEN1 Duodenopancreatic Neuroendocrine Tumors.
Bulzico D
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1301-e1302. PubMed ID: 37646771
[No Abstract] [Full Text] [Related]
9. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
Sadowski SM; Pieterman CRC; Perrier ND; Triponez F; Valk GD
Endocr Relat Cancer; 2020 Jun; 27(6):R145-R161. PubMed ID: 32229700
[TBL] [Abstract][Full Text] [Related]
11. Plasma Polyamines as an Additional to Imaging Biomarker in MEN1 Patients With Duodenopancreatic Neuroendocrine Tumors.
Kassi E; Kaltsas G
J Clin Endocrinol Metab; 2022 Jan; 107(2):e880-e882. PubMed ID: 34543418
[No Abstract] [Full Text] [Related]
12. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
Marini F; Giusti F; Tonelli F; Brandi ML
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
[TBL] [Abstract][Full Text] [Related]
15. Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.
Walls GV; Reed AA; Jeyabalan J; Javid M; Hill NR; Harding B; Thakker RV
Endocrinology; 2012 Nov; 153(11):5167-79. PubMed ID: 23024266
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).
Lopez CL; Joos B; Bartsch DK; Manoharan J; Albers M; Slater EP; Bollmann C; Roth S; Bayer A; Fendrich V
World J Surg; 2019 Mar; 43(3):831-838. PubMed ID: 30600364
[TBL] [Abstract][Full Text] [Related]
18. One-Year Postoperative Mortality in MEN1 Patients Operated on Gastric and Duodenopancreatic Neuroendocrine Tumors: An AFCE and GTE Cohort Study.
Christou N; Mathonnet M; Gaujoux S; Cadiot G; Deguelte S; Kraimps JL; Lifante JC; Menegaux F; Mirallié E; Muscari F; Carnaille B; Pattou F; Sauvanet A; Goudet P
World J Surg; 2019 Nov; 43(11):2856-2864. PubMed ID: 31384998
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model.
Manoharan J; Fendrich V; Di Fazio P; Bollmann C; Roth S; Joos B; Mintziras I; Albers MB; Ramaswamy A; Bertolino P; Zhang CX; Slater EP; Bartsch DK; Lopez-Lopez CL
Neuroendocrinology; 2018; 107(3):257-266. PubMed ID: 30025403
[TBL] [Abstract][Full Text] [Related]
20. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
Bartsch DK; Slater EP; Albers M; Knoop R; Chaloupka B; Lopez CL; Fendrich V; Kann PH; Waldmann J
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2387-91. PubMed ID: 25210877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
